Treatment with thalidomide and cyclophosphamide (TCID) is superior to vincristine (VID) and to vinorelbine (VRID) regimens in patients with refractory or recurrent multiple myeloma - Auel, Britta; Goldschmidt, Hartmut; Möhler, Thomas (Indian journal of hematology and blood transfusion, 2012)
Published online: 18 August 2011